p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

By Robert J Ihry, Kathleen A. Worringer, M. Salick, Elizabeth Frias, Daniel J. Ho, Kraig M. Theriault, Sravya Kommineni, Julie T. Chen, M. Sondey, Chaoyang Ye and 10 more. Nature Medicine, 2018

867 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/a7b90250a4fc1ed8be4241a34709186d5a525d1e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Howard Y. Chang
2. Luke A. Gilbert
3. Jonathan S. Weissman
4. Min Wu
5. Mengyuan Huang
6. Hongyi Li
7. Xia Zhao
8. Yang Yang

Citations in the corpus

• Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects (2020, background): “Recent studies have further highlighted other issues affecting delivery efficiency, including the immune risk of host tumors and cells to Cas9 proteins,(325) as well as the DSB P53 responses related to genome editing.(326) Many new viral and nonviral systems have been developed to overcome these pro”
• Genome-wide Programmable Transcriptional Memory by CRISPR-based Epigenome Editing (2021, background): “CRISPRoff gene silencing can lead to effectively complete nulls without inducing a DNA damage response facilitating multigene targeting screens or therapeutic cell engineering (Ihry et al., 2018).”
• CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future (2020, background): “Further safety concerns were revealed when using this tool in human pluripotent stem cells (hPSCs) which demonstrated that p53 activation in response to the toxic DSBs introduced by CRISPR often triggers subsequent apoptosis (69).”